drugset / Trial / NCT04710303
COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral Platform in Healthy South African Adults
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a phase 1b, open-label study in adult healthy participants. This clinical trial is designed to assess the safety, reactogenicity, and immunogenicity of the hAd5-S-Fusion+N-ETSD vaccine and select a dose for future studies.
Timeline
- Start
- 2021-03-02
- Primary completion
- 2022-08-02
- Completion
- 2022-08-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | hAd5-S-Fusion+N-ETSD | Vaccine | 4e+10 unknown | Intranasal |
| Subject | hAd5-S-Fusion+N-ETSD | Vaccine | 5e+10 unknown | Intranasal |
| Subject | hAd5-S-Fusion+N-ETSD | Vaccine | 1e+11 unknown | Intranasal |